@article{e9dff431312b4e188ff6d5353bb6492e,
title = "Incidence and Outcomes of Acute Heart Failure with Preserved Versus Reduced Ejection Fraction in SPRINT",
abstract = "Background: In the SPRINT (Systolic Blood Pressure Intervention Trial), intensive BP treatment reduced acute decompensated heart failure (ADHF) events. Here, we report the effect on HF with preserved ejection fraction (HFpEF) and HF with reduced EF (HFrEF) and their subsequent outcomes. Methods: Incident ADHF was defined as hospitalization or emergency department visit, confirmed, and formally adjudicated by a blinded events committee using standardized protocols. HFpEF was defined as EF ≥45%, and HFrEF was EF <45%. Results: Among the 133 participants with incident ADHF who had EF assessment, 69 (52%) had HFpEF and 64 (48%) had HFrEF (P value: 0.73). During average 3.3 years follow-up in those who developed incident ADHF, rates of subsequent all-cause and HF hospital readmission and mortality were high, but there were no significant differences between those who developed HFpEF versus HFrEF. Randomization to the intensive arm had no effect on subsequent mortality or readmissions after the initial ADHF event, irrespective of EF subtype. During follow-up among participants who developed HFpEF, although relatively modest number of events limited statistical power, age was an independent predictor of all-cause mortality, and Black race independently predicted all-cause and HF hospital readmission. Conclusions: In SPRINT, intensive BP reduction decreased both acute decompensated HFpEF and HFrEF events. After initial incident ADHF, rates of subsequent hospital admission and mortality were high and were similar for those who developed HFpEF or HFrEF. Randomization to the intensive arm did not alter the risks for subsequent all-cause, or HF events in either HFpEF or HFrEF. Among those who developed HFpEF, age and Black race were independent predictors of clinical outcomes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.",
keywords = "blood pressure, heart failure, hypertension, lipids, myocardial infarction",
author = "Bharathi Upadhya and Willard, {James J.} and Lovato, {Laura C.} and Rocco, {Michael V.} and Lewis, {Cora E.} and Suzanne Oparil and Cushman, {William C.} and Bates, {Jeffrey T.} and Bello, {Natalie A.} and Gerard Aurigemma and Johnson, {Karen C.} and Rodriguez, {Carlos J.} and Raj, {Dominic S.} and Anjay Rastogi and Leonardo Tamariz and Alan Wiggers and Kitzman, {Dalane W.}",
note = "Funding Information: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kitzman reported receiving personal fees from Merck, Forest Labs, and Abbvie; personal fees and other from Gilead and Relypsa; and grants from Novartis outside the submitted work. Dr Oparil reported receiving personal fees from Forest Laboratories Inc; grants, personal fees, and nonfinancial support from Medtronic; personal fees from Amgen (Onyx is subsidiary); grants and personal fees from AstraZeneca and Bayer Healthcare Pharmaceuticals Inc; personal fees from Boehringer-Ingelheim and GlaxoSmithKline; grants from Merck and Co; and serving as co-chair for the Eighth Joint National Committee. Dr Cushman reported receiving institutional grants from Eli Lilly and Boehringer Ingelheim and has provided uncompensated consultation to Takeda Pharmaceuticals. Dr Upadhya reported receiving honoraria from Novartis and Corvia. Dr Rocco reported receiving honoraria outside the present study from his work as a consultant for Abbvie, Baxter, and George Clinical and grant funding outside the present study from Bayer and GlaxoSmithKline. Dr Bello reported research funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23 HL136853, R01 HL153382) outside the present study. The other authors report no conflicts. Funding Information: We also acknowledge the support from the following Clinical and Translational Science Awards funded by the National Center for Advancing Translational Sciences: Case Western Reserve University, UL1TR000439; Ohio State University, UL1RR025755; University of Pennsylvania, UL1RR024134 and UL1TR000003; Boston University, UL1RR025771; Stanford University, UL1TR000093; Tufts University, UL1RR025752, UL1TR000073, and UL1TR001064; University of Illinois, UL1TR000050; University of Pittsburgh, UL1TR000005; University of Texas Southwestern, 9U54TR000017-06; University of Utah, UL1TR000105-05; Vanderbilt University, UL1 TR000445; George Washington University, UL1TR000075; University of California, Davis, UL1 TR000002; University of Florida, UL1 TR000064; University of Michigan, UL1TR000433; and Tulane University, P30GM103337 Centers of Biomedical Research Excellence Award/National Institute of General Medical Sciences. Support was also received in part by NIH grants R01AG18915, 1R01HL107257, P30AG021332, and R01AG020583 (Dr Kitzman). Funding Information: The SPRINT trial (Systolic Blood Pressure Intervention Trial) is funded with federal funds from the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke, under contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and Inter-Agency Agreement A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of article writing and revision were performed by the coauthors. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs, or the US government. For a full list of contributors to SPRINT, please see the supplementary acknowledgement list: https://www.sprinttrial.org/public/dspScience.cfm . Publisher Copyright: {\textcopyright} 2021 American Heart Association, Inc.",
year = "2021",
month = dec,
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.121.008322",
language = "English (US)",
volume = "14",
pages = "1291--1301",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "12",
}